| __timestamp | Regeneron Pharmaceuticals, Inc. | Sanofi |
|---|---|---|
| Wednesday, January 1, 2014 | 504755000 | 8565000000 |
| Thursday, January 1, 2015 | 838526000 | 9496000000 |
| Friday, January 1, 2016 | 1177697000 | 9592000000 |
| Sunday, January 1, 2017 | 1320433000 | 10164000000 |
| Monday, January 1, 2018 | 1556200000 | 9934000000 |
| Tuesday, January 1, 2019 | 1834800000 | 9883000000 |
| Wednesday, January 1, 2020 | 1346000000 | 9390000000 |
| Friday, January 1, 2021 | 1824900000 | 9555000000 |
| Saturday, January 1, 2022 | 2115900000 | 10539000000 |
| Sunday, January 1, 2023 | 2631300000 | 10765000000 |
| Monday, January 1, 2024 | 2954400000 | 9183000000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry giants is crucial. Over the past decade, Sanofi and Regeneron Pharmaceuticals have demonstrated contrasting approaches to managing Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Sanofi consistently outspent Regeneron, with SG&A expenses peaking at approximately $10.8 billion in 2023, a 26% increase from 2014. In contrast, Regeneron's SG&A expenses grew more dramatically, surging over 400% from $505 million in 2014 to $2.6 billion in 2023. This stark difference highlights Sanofi's steady investment in administrative functions, while Regeneron has rapidly scaled its operations. These trends reflect broader strategic priorities, with Sanofi focusing on maintaining its market position and Regeneron aggressively expanding its footprint. As the pharmaceutical industry evolves, these financial strategies will continue to shape the competitive dynamics between these two powerhouses.
R&D Insights: How Sanofi and Regeneron Pharmaceuticals, Inc. Allocate Funds
Cost Management Insights: SG&A Expenses for Sanofi and Rhythm Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Sanofi and ADMA Biologics, Inc.
Who Optimizes SG&A Costs Better? Sanofi or Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Dr. Reddy's Laboratories Limited
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Evotec SE